Background: With the establishment of new technologies in the search for a cure for hemophilia, non-pharmacological treatments have had a more important role in increasing life expectancy, quality of life of children suffering from hemophilia disorders. The aim of the systematic review was a comprehensive understanding of Non-pharmacological treatment on Iranian childr...

J Adv Med Educ Prof. July 2015; Vol 3 No 3 Dear Editor, A hemophilia is a chronic bleeding disease and can interfere with daily performance of children, these children require continuous training to prevent bleeding and take timely action (1). Since children nurses play an important role in the education of involved children and their Selfefficacy and also due to today’s approach which is using...

Individuals with hemophilia are deficient in one of the clotting factor proteins that are vital in the formation of a clot. Classic hemophilia or hemophilia A is a deficiency of factor VIII, while Christmas Disease or Hemophilia B is a deficiency of factor IX. The deficiency of one of these proteins comes about because of a mutation on the X chromosome. Patients with both types of hemophilia ar...

Regular prophylactic treatment in severe hemophilia should be considered an optimal treatment. There is no general agreement on the optimal prophylaxis regimen, and adherence to prophylaxis is a main challenge due to medical, psychosocial, and cost controversies. Improved approaches in prophylaxis regimen of hemophilia B are needed to make patients' lives easier. There is some evidence to suppo...

Hemophilia is a hereditaty coagulation disorder which is inherited as an X-link recessive trait. Disorder happens in the intrinsic hemostasis pathway, in which there is a deficiency or defect of coagulation factor VIII (Hemophilia A) or IX (Hemophilia B). Hemophilia is comnron in male, though occurrence in female has also been reported. Female usually are carries. Immunologically, there are sev...

Although hemophilia has a potentially high economic impact, published estimates of health care costs for Americans with hemophilia are sparse and non-specific as to the non-bleeding complications of the disease. The objective of this study is to estimate average annual health care expenditures for people with hemophilia covered by employer-sponsored insurance, stratified according to the influe...

Background: Hemophilia B is an X-linked hereditary disorder of blood coagulation system which is caused by factor IX (FIX) deficiency. Factor IX is a plasma glycoprotein that participates in the coagulation process leading to the generation of fibrin. Replacement of factor IX with plasma-derived or recombinant factor IX is the conventional treatment for hemophilia B to raise the factor IX le...

BACKGROUND AND OBJECTIVE We describe our three year experience in genetic counseling at the Castelfranco Veneto Hemophilia Center, Italy. DESIGN AND METHODS A total of 258 individuals were involved in the study of 142 females. These formed 40 families with hemophilia A and 6 families with hemophilia B. Following pedigree analysis, the FVIII inversion was first examined in severe hemophilia A ...

The ability of factor VIIa to initiate thrombin generation and clot formation in blood from healthy donors, blood from patients with hemophilia A, and in anti-factor IX antibody-induced ("acquired") hemophilia B blood was investigated. In normal blood, both factor VIIa-tissue factor (TF) complex and factor VIIa alone initiated thrombin generation. The efficiency of factor VIIa was about 0.0001 ...

Introduction. Advances in hemophilia care and treatment have led to increases in the life expectancy among hemophiliacs. As a result, persons with hemophilia are reaching an older age and experiencing various age-related health conditions never seen before in this population. Aim. To determine the prevalence of comorbidities among middle-aged and elderly hemophilia A and hemophilia B patients. ...